Search Videos and More
News
Dana-Farber Research Helps Drive FDA Label Update for Primary CNS Lymphoma
Change removes prior exclusion and may expand access to CAR T-cell therapy for eligible relapsed or refractory patients
News
CD123 Targeted Therapies
CD123 is the alpha subunit of the interleukin 3 (IL-3) receptor. It pairs with a beta subunit, CD131, to transmit cytokine signals from the outside to inside of several types of immune and hematopoietic cells. CD123 is highly expressed on the cell surface of several blood cancers.
News
A Brighter Future for B-ALL in Adults
Acute lymphoblastic leukemia (ALL) in adults has been historically associated with dismal clinical outcomes. Fortunately, adults diagnosed with ALL are now more likely to experience a favorable response to treatment due to ongoing improvements in immunotherapy.
News
Bringing Specialists Together: Tandem Leukemia and Stem Cell Transplant Consults
Allogeneic hematopoietic stem cell transplantation (allo-HCT) is a cornerstone of curative therapy for patients with high-risk hematologic malignancies.
News
New Diagnostic Tool Developed at Dana-Farber Revolutionizes Acute Leukemia Diagnosis
Researchers at Dana-Farber Cancer Institute have developed a groundbreaking diagnostic tool that could transform the way acute leukemia is identified and treated.
News
Clinical Trials and Research for Mantle Cell Lymphoma
Dana-Farber Cancer Institute is at the forefront of research in mantle cell lymphoma. We seek to advance more effective treatment options and reduce treatment side effects for patients with mantle cell lymphoma.
News
Dana-Farber Researchers Find Less Treatment May be More in Mantle Cell Lymphoma
For a long time, the standard treatment for younger patients with newly diagnosed mantle cell lymphoma involved intensive chemotherapy, called induction therapy, followed by autologous stem cell transplant (ASCT, where the patient’s own stem cells are used), followed by maintenance therapy to help keep the cancer from coming back.
News
TILs: What Are They and How Are They Used in Cancer Treatment?
Tumor-infiltrating lymphocyte, or TIL, therapy uses a patient’s own immune system T cells to fight cancer.
News
Years of Research Help Forge a New Path in Hodgkin Lymphoma Treatment
Medical advances tend to unfold slowly over many years, fueled by successive clinical studies that build upon each other and together provide the evidence needed to change patient care.
News
Continuing to Advance the Standard of Care for Newly Diagnosed and Relapsed/Refractory Multiple Myeloma
Dana-Farber Cancer Institute continues to lead the way in clinical research to further improve longevity and quality of life for our patients with multiple myeloma (MM).
News
Novel Approaches in Waldenström's Macroglobulinemia
Dana-Farber Cancer Institute researchers will present important research studies during the 2025 ASCO Genitourinary (GU) Cancers Symposium, on February 13-15, 2025, in San Francisco, Calif.
News
Dana-Farber Researchers to Present Key Transplant and Cellular Therapy Studies at 2025 Tandem Meetings
Dana-Farber Cancer Institute researchers presented key research studies at the 2025 Tandem Meetings, the premier conference in hematopoietic cell transplantation (HCT) and cellular therapy.